BIOCRYST PHARMACEUTICALS INC
Close on Oct 19, 2026
- Market cap
- $2.14B
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 2, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 5, 2026 | Before market open | $218.30M | $0.30 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 6, 2026 | Before market open | – | – | – |
| Q4 FY2025 Ended Dec 31, 2025 | Feb 26, 2026 | Before market open | $406.56M | $1.12 | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 3, 2025 | Before market open | $159.40M | $0.06 | $0.16 |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 4, 2025 | Before market open | $163.40M | $0.02 | $0.15 |
| Q1 FY2025 Ended Mar 31, 2025 | May 5, 2025 | Before market open | $145.50M | $0.00 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Feb 24, 2025 | Before market open | $131.50M | $-0.13 | $-0.13 |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 4, 2024 | Before market open | $117.10M | $-0.07 | $-0.07 |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 5, 2024 | Before market open | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 6, 2024 | Before market open | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Feb 26, 2024 | Before market open | – | – | – |
Company guidance
Outlook given with results on Aug 5, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| non-GAAP operating expensesnon-GAAP | full year 2026 | $420.00M to $440.00M | Lowered |
| ORLADEYO revenue | full year 2026 | $625.00M to $645.00M | Lowered |
| total revenue | full year 2026 | $690.00M to $715.00M | Raised |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements Biocryst Pharmaceuticals filed with the SEC
BioCryst Reports Second Quarter 2026 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
BioCryst Sharpens Scientific Focus on External Innovation with Wind Down of Internal Discovery Programs and Closure of Birmingham Research Facility
Exit or restructuring costs · Regulation FD disclosure · EX-99.1 to Form 8-K
BioCryst Reports First Quarter 2026 Financial Results and Provides Business Update
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
BioCryst Announces European Licensing Agreement with Irish Affiliate of Neopharmed Gentili for Navenibart in Hereditary Angioedema
Regulation FD disclosure · EX-99.1 to Form 8-K
BioCryst Reports Full Year 2025 Financial Results and Provides Business Update
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
BioCryst Completes Acquisition of Astria Therapeutics, Expanding Leadership in Hereditary Angioedema
Material agreement · Acquisition or disposition completed · New financial obligation · Regulation FD disclosure · EX-99.1 to Form 8-K
(In thousands, except share and per share data)
Material agreement · Acquisition or disposition completed · New financial obligation · Regulation FD disclosure · EX-99.2 to Form 8-K
Report of Independent Registered Public Accounting Firm
Material agreement · Acquisition or disposition completed · New financial obligation · Regulation FD disclosure · EX-99.3 to Form 8-K
BioCryst Announces Preliminary Full Year 2025 ORLADEYO® (berotralstat) Net Revenue of $601 Million (+37 percent y-o-y), Beating Prior Guidance Range
Results of operations · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
BioCryst Announces FDA Approval of ORLADEYO®
Other events · EX-99.1 to Form 8-K
BioCryst Receives Early Termination of HSR Waiting Period for Astria Acquisition
Other events · EX-99.1 to Form 8-K
BioCryst Reports Third Quarter 2025 Financial Results and Provides Business Update
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
certain stockholders of ASTRIA THERAPEUTICS, INC.
Material agreement · Results of operations · Executive or director change · Other events · EX-99.1 to Form 8-K
BioCryst to Acquire Astria Therapeutics, Strengthening Presence in HAE, Transforming Growth Profile
Material agreement · Results of operations · Executive or director change · Other events · EX-99.2 to Form 8-K
October 14, 2025 BioCryst to Acquire Astria Therapeutics
Material agreement · Results of operations · Executive or director change · Other events · EX-99.3 to Form 8-K
BioCryst Completes Sale of European ORLADEYO ® (berotralstat) Business
Material agreement · Other events · EX-99.1 to Form 8-K
BioCryst Reports Second Quarter 2025 Financial Results and Provides Business Update
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
BioCryst Announces Charlie Gayer to Succeed Jon Stonehouse as Chief Executive Officer Upon his Retirement in December
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
BioCryst Appoints Babar Ghias Chief Financial Officer and Head of Corporate Development
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
BioCryst Announces Sale of European ORLADEYO® (berotralstat) Business to Neopharmed Gentili for up to $264 Million
Other events · EX-99.1 to Form 8-K
BioCryst Reports First Quarter 2025 Financial Results and Provides Business Update
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
BioCryst Reports Fourth Quarter and Full Year 2024 Financial Results and Upcoming Key Milestones
Results of operations · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
BioCryst Announces Preliminary Full Year 2024 ORLADEYO® (berotralstat) Net Revenue of $437 Million (+34 percent y-o-y)
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
BioCryst Reports Third Quarter 2024 Financial Results and Provides Business Update
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
BioCryst Begins Enrollment in Phase 1 Trial Evaluating BCX17725, a KLK5 Inhibitor, for the Treatment of Netherton Syndrome
Regulation FD disclosure · EX-99.1 to Form 8-K
U.S. Government Awards BioCryst $69 Million RAPIVAB® (peramivir injection) Contract for Strategic National Stockpile
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
BioCryst Reports Second Quarter 2024 Financial Results and Provides Business Update
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
BioCryst Reports First Quarter 2024 Financial Results and Provides Business Update
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
BioCryst Reports Fourth Quarter and Full Year 2023 Financial Results and Upcoming Key Milestones
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
BioCryst Announces Preliminary Full Year 2023 ORLADEYO® (berotralstat) Net Revenue of $325 Million, Provides 2024 Guidance and Accelerated Path to Profitability
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
BioCryst R&D Day Highlights New Diversified Pipeline of First-in-Class/Best-in-Class Therapies with Five Programs Expected in Clinical Development in Next 24 Months
Regulation FD disclosure · EX-99.1 to Form 8-K
BioCryst and Clearside Biomedical Enter Partnership to Develop Avoralstat for Diabetic Macular Edema Using Clearside’s Proprietary SCS Microinjector®
Regulation FD disclosure · EX-99.1 to Form 8-K
BioCryst Reports Third Quarter 2023 Financial Results and Provides Business Update
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
BioCryst Begins Enrollment in Proof-of-Concept Trial to Confirm Safe, Effective, Once-daily Dose of Oral Factor D Inhibitor, BCX10013
Regulation FD disclosure · EX-99.1 to Form 8-K
BioCryst Reports Second Quarter 2023 Financial Results and Provides Business Update
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
BioCryst Reports First Quarter 2023 Financial Results and Provides Business Update
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
BioCryst Refinances Existing Debt with $450 Million Financing Commitment from Pharmakon
Material agreement · New financial obligation · Regulation FD disclosure · EX-99.1 to Form 8-K
BioCryst Reports Fourth Quarter and Full Year 2022 Financial Results and Upcoming Key Milestones
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
BioCryst Announces Preliminary Full Year 2022 ORLADEYO® (berotralstat) Net Revenue and Provides Full Year 2023 ORLADEYO Net Revenue Guidance
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K